Abstract:AIMS:We conducted a presentation on an 84-year-old male patient who has been diagnosed with TTRA81V (p. TTRA101V) hereditary transthyretin cardiac amyloidosis (hATTR-CM). In order to establish its pathogenicity, we extensively investigated the biochemical and biophysical properties of the condition. METHODS AND RESULTS:Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly acknowledged progressive infiltrative cardiomyopathy that leads to heart failure and potentially fatal arrhythmias. Gaining a comprehensive understanding of the biochemical and biophysical characteristics of genetically mutated TTR proteins serves as the fundamental cornerstone for delivering precise medical care to individuals affected by ATTR. Laboratory assessments indicated a brain natriuretic peptide of 200.12 ng/L (normal range: 0-100 ng/L) and high-sensitivity cardiac troponin I of 0.189 μg/L (normal range: 0-0.1 μg/L). Echocardiography identified left atrial enlargement, symmetrical left ventricular hypertrophy (16 mm septal and 16 mm posterior wall), and a left ventricular ejection fraction of 56%. Cardiac-enhanced magnetic resonance imaging revealed subendocardial late gadolinium enhancement. Tc-99m-PYP nuclear scintigraphy confirmed grade 3 myocardial uptake, showing an increased heart-to-contralateral ratio (H/CL = 2.33). Genetic testing revealed a heterozygous missense mutation in the TTR gene (c.302C>T), resulting in an alanine-to-valine residue change (p. Ala81Val, following the first 20 residues of signal sequence nomenclature). Biochemical analysis of this variant displayed compromised kinetic stability in both the TTRA81V:WT (wild-type) heterozygote protein (half-life, t1/2 = 21 h) and the TTRA81V homozygote protein (t1/2 = 17.5 h). The kinetic stability fell between that of the TTRWT (t1/2 = 42 h) and the early-onset TTRL55P mutation (t1/2 = 4.4 h), indicating the patient's late-onset condition. Kinetic stabilizers (Tafamidis, Diflunisal, and AG10) all exhibited the capacity to inhibit TTRA81V acid- and mechanical force-induced fibril formation, albeit less effectively than with TTRWT. Chromatographic assessment of the patient's serum TTR tetramers indicated a slightly lower concentration (3.0 μM) before oral administration of Tafamidis compared with the normal range (3.6-7.2 μM). CONCLUSIONS:We identified a patient with hATTR-CM who possesses a rare TTRA81V mutation solely associated with cardiac complications. The slightly reduced kinetic stability of this mutation indicates its late-onset nature and contributes to the gradual progression of the disease.

The Structural and Dynamic Insights into the Ala97Ser Amyloidogenic Mutation in Transthyretin

A molecular basis for tetramer destabilization and aggregation of transthyretin Ala97Ser

Conformational Dynamics of an Amyloidogenic Intermediate of Transthyretin: Implications for Structural Remodeling and Amyloid Formation

The Physical Driving Forces of Conformational Transition for TTR91-96 with Proline Mutations.

Characterization of an amyloidogenic intermediate of transthyretin by NMR relaxation dispersion

Probing the Structural and Functional Link Between Mutation- and Ph-Dependent Hydration Dynamics and Amyloidosis of Transthyretin

Probing the Dissociation Pathway of a Kinetically Labile Transthyretin Mutant

Transthyretin mutagenesis: impact on amyloidogenesis and disease

Biochemical and Biophysical Properties of an Unreported T96R Mutation Causing Transthyretin Cardiac Amyloidosis

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)

Clinical and molecular insights into A97S variants in hereditary transthyretin amyloid polyneuropathy in South China

Biochemical and Biophysical Properties of a Rare TTRA81V Mutation Causing Mild Transthyretin Amyloid Cardiomyopathy

Structural and thermodynamic characterization of a highly amyloidogenic dimer of transthyretin involved in a severe cardiomyopathy

Characterization of Transthyretin Mutation G47V Associated with Hereditary Cardiac Amyloidosis

Mutation and low pH effect on the stability as well as unfolding kinetics of transthyretin dimer.

Nanoscale structural characterization of transthyretin aggregates formed at different time points of protein aggregation using atomic force microscopy-infrared spectroscopy

The Impact of V30A Mutation on Transthyretin Protein Structural Stability and Cytotoxicity Against Neuroblastoma Cells.

Clinical and Biochemical Characterization of Hereditary Transthyretin Amyloidosis Caused by E61K Mutation

Histidine tautomerism-mediated transthyretin amyloidogenesis: A molecular insight

Atomic Mechanisms of Transthyretin Tetramer Dissociation Studied by Molecular Dynamics Simulations

Characterization of Non-amyloidogenic G101S Transthyretin